Daniel A. Lawrence, PhD

Daniel Lawrence, PhD, is the Frederick G L Huetwell Professor of Basic Research in Cardiovascular Medicine, Professor of Cardiovascular Medicine, and Professor of Molecular and Integrative Physiology. He received his PhD in Molecular Biology from Umeå University, (Sweden) in 1989 and completed postdoctoral training at the University of Michigan in 1992. He is a recognized leader in the field of neuroscience with extensive experience in murine models of CNS disease. Dr. Lawrence is also an expert on the molecular and cell biology of tissue plasminogen activator (tPA) and its actions in the CNS. He has had continuous research support from NIH since 1991 and has published over 160 peer-reviewed scientific articles in top journals. Dr. Lawrence has 25 issued patents and is the founder MDI Therapeutics, Inc. a pharmaceutical company developing therapies for the treatment of fibroproliferative disorders. Dr. Lawrence will serve as a Subaward Principal Investigator on this project.